90370-29-9

Usage

Uses

Used in Phototherapy Applications:
4,4',6-Trimethylangelicin is used as a photosensitizer for phototherapy, particularly for treating certain skin conditions. Its phototoxic and photoactivating properties allow it to absorb light and generate reactive oxygen species, which can help in managing the symptoms and progression of skin disorders.
Used in Pharmaceutical Industry:
4,4',6-Trimethylangelicin is used as a potential therapeutic agent for anti-cancer and anti-inflammatory applications. Its biological activities are being studied for the development of drugs targeting cancer cells and reducing inflammation in various diseases and conditions.

InChI:InChI=1/C14H12O3/c1-7-5-11(15)17-14-10(7)4-8(2)13-12(14)9(3)6-16-13/h4-6H,1-3H3

Upstream product

• 90370-26-6 <(4,6-dimethyl-8-acetyl-7-coumarinyl)oxy>acetic acid 
• 90370-20-0 4,6-dimethyl-7-hydroxy-8-acetylcoumarin 
• 90370-17-5 7-acetoxy-4,6-dimethyl benzopyran-2(H)-one 
• 90370-23-3 ethyl <(4,6-dimethyl-8-acetyl-7-coumarinyl)oxy>acetate 

Relevant academic research and scientific papers

Method of preparing photochemotherapic alkylangelicin compounds

The alkylangelicins according to the invention are obtained starting from an umbelliferone, in which the 6-position is already substituted by an alkyl group; in such a way the 7-allyloxy or 7-acyloxy umbelliferone intermediates can form by transposition of the allyl or acyl group only the 8-allyl and 8-acyl derivatives, and therefore the presence, even in traces, of psoralens is absolutely excluded in the subsequent synthetic steps. The 6-alkylangelicins thus obtained are particularly usable for the photochemotherapy of psoriasys and of other skin diseases characterized by cellular hyperproliferation, as well as for the photochemotherapy of vitiligo and of alopecia aerata.

6-Methylangelicins: A New Series of Potential Photochemotherapeutic Agents for the Treatment of Psoriasis

The possible presence of methylpsoralens as undesired inquinants in synthetic methylangelicins has been avoided through a synthetic pathway starting from umbelliferones carrying a methyl group in the 6-position.The new 6-methylangelicins show a high affinity toward DNA, forming in the dark a molecular complex; the complexed angelicins under UV-A irradiation photobind effectively to the macromolecule, forming only monoaducts.The new compounds show an evident antiproliferative activity by inhibiting DNA synthesis on Ehrlich cells; great differences, however, can be seen between the various compounds.All the compounds are lacking of skin erythemogenic activity.Some of the new 6-methylangelicins, evaluated in terms of mutagenic activity, demonstrate to be lees effective than 8-methoxypsoralen (8-MOP), used for a comparison.On the basis of antiproliferative activity, lack of skin phototoxicity, and low mutagenicity, two compounds have been chosen for clinical evaluation.The compounds tested on seven psoriatic patients by topical application and UV-A irradiation proved to be more effective than 8-MOP, used in the same conditions.